- Home
- NVRI vs INVA Comparison
NVRI vs INVA Comparison
Compare NVRI & INVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVRI | INVA |
|---|---|---|
| Founded | 1853 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2026 | 2000 |
Fundamental Metrics
Financial Performance| Metric | NVRI | INVA |
|---|---|---|
| Price | $21.86 | $22.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $32.80 |
| AVG Volume (30 Days) | ★ 2.0M | 719.9K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 816.67 |
| EPS | N/A | ★ 2.22 |
| Revenue | N/A | ★ $217,217,000.00 |
| Revenue This Year | $3.87 | $8.95 |
| Revenue Next Year | $3.70 | $12.65 |
| P/E Ratio | ★ N/A | $10.02 |
| Revenue Growth | N/A | ★ 62.63 |
| 52 Week Low | $7.70 | $16.52 |
| 52 Week High | $22.14 | $25.15 |
Technical Indicators
Market Signals| Indicator | NVRI | INVA |
|---|---|---|
| Relative Strength Index (RSI) | 61.87 | 50.57 |
| Support Level | $17.94 | $22.20 |
| Resistance Level | N/A | $23.03 |
| Average True Range (ATR) | 1.40 | 0.56 |
| MACD | 0.16 | 0.08 |
| Stochastic Oscillator | 97.29 | 58.62 |
Price Performance
Historical ComparisonAbout NVRI Enviri Corporation
Enviri Corp is a market-leading, provider of environmental solutions for industrial and specialty waste streams, and equipment and technology for the rail sector. The company's current operations consist of three divisions: Harsco Environmental, Harsco Rail, and Clean Earth. The company gains its revenue from Harsco Environmental segment. Geographically company operates in USA and International Countries, with majority revenue from USA.
About INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.